Achievements

MAJOR ACHIEVEMENTS

  • Produced 625 M. Phil and 208 Ph.Ds. Scientists working in different fields published 990 research articles with impact factor of 2206 till date.
  • Approval for general cultivation of transgenic triple gene cotton variety (CKC-05), developed at Centre of Excellence in Molecular Biology (CEMB), by Punjab Seed Council in its 57th Meeting. CKC-01 and CKC-03 developed at CEMB are already available on the market.
  • Significant enhancement of wound healing in diabetic individuals by utilizing stem cells derived from a patient’s own lipoaspirate, combined with platelet-rich plasma during a clinical trial conducted in partnership with Jinnah Burn and Reconstructive Surgery Centre, Lahore.
  • Successful facial reconstruction using autologous lipoaspirate-derived stem cell suspension supplemented with SVF, marking a significant advancement in medical treatment, in collaboration with Jinnah Burn and Reconstructive Surgery Centre, Lahore
  • Achieved the development and commercialization of biosimilar products, including Recombinant Human Interleukin-11 (Oprelvekin), a drug that boosts white blood cell production and aids in platelet enhancement.
  • In house development of essential products like 2X PCR Mix, 2X HotStart Mix, and 2X qPCR Mix, each designed to facilitate molecular biology research and applications.
  • Development of recombinant human G-CSF (Filgrastum), a drug crucial for treating Neutropenia, a condition characterized by a deficiency of white blood cell neutrophils.
  • The development of a novel compound showing potential for combating liver fibrosis in mice, and a patent has been filed for this discovery.
  • Successful induction of GhEXPA8 fiber expansion gene into cotton plants, leading to improved qualities of cotton fibers.
  • Identification of specific transcripts related to drought tolerance in Agave sisalana, helping to develop more resilient plants.
  • Collaboration with seed companies to establish fourteen agreements and shared cotton lines with two beneficial genes, encouraging adoption by farmers and generating revenue.
  • Groundbreaking work resulted in the approval of field trials for innovative cotton lines containing three genes. We secured patents for these new CEMB-Klean Cotton varieties (CKC-1, CKC-02, CKC-03, CKC-04, CKCKC-05 & CKC-06), which are revolutionizing cotton farming practices.
  • Improvement of the composition of the wax layer on the plant’s surface by the tranfer of Arabidopsis wax gene into Gossypium hirsutum (cotton). This enhances the plant’s ability to withstand challenges and increases productivity.
  • Using genetic manipulation, the length of fibers in desi cotton was significantly increased. This achievement holds great promise for the cotton industry’s future.
  • Through immunization with the HA protein, immune responses in mice were triggered, contributing to the development of plant-based Avian Influenza vaccines.
  • Introduction of F and HN protein genes into maize, leading to immunogenic reactions against NDV in chicks. This demonstrates the potential for plant-based methods in controlling diseases.
  • Using CRISPR/Cas9 technology, transgenic cotton plants with CLCuV gene knockouts were engineered, making them resistant to virus infections.
  • 150 different transgenic maize lines have been successfully evaluated across various locations. This ensures the development of high-performing maize varieties that can thrive in diverse environments
  • We extended our influence through a Memorandum of Understanding (MOU) for transferring CEMB CKC Technology to African nations. This highlights our dedication to global collaboration and the sharing of knowledge.
  • Identification of two indigenous plant-derived compounds with anti-HCV potential has led to patent filings, offering new avenues for hepatitis C treatment.
  • miRNA-221, found differentially regulated in specific breast cancer patients, holds promise as a potential biomarker for diagnosing breast cancer grades.
  • Exploration of Euphorbia pilulifera leaf extract revealed its potential for hepatoprotection, anti-inflammatory effects, and acetylcholinesterase inhibition.
  • Development of PCR-based diagnostic kits for Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Dengue, contributing to accurate and efficient disease detection.
  • Development of an innovative in-house ELISA for detecting antibodies against the Hepatitis Delta virus antigen of Pakistani origin, enhancing diagnostic capabilities.
  • The potential of targeting the hepatitis C virus internal ribosomal entry site (IRES) as an effective antiviral strategy was demonstrated utilizing CRISPR-Cas13a technology.
  • Discovery of 26 new deafness-related genetic locations, a novel deafness modifier gene, 25 new genetic locations, and 21 novel genes associated with vision impairment. Additionally, we have identified 52 novel genes linked to Intellectual Disability.
  •